|
1
|
Filho AM, Laversanne M, Ferlay J, Colombet
M, Piñeros M, Znaor A, Parkin DM, Soerjomataram I and Bray F: The
GLOBOCAN 2022 cancer estimates: Data sources, methods, and a
snapshot of the cancer burden worldwide. Int J Cancer.
156:1336–1346. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Peng L, Jiang J, Tang B, Nice EC, Zhang YY
and Xie N: Managing therapeutic resistance in breast cancer: From
the lncRNAs perspective. Theranostics. 10:10360–10377. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen S, Paul MR, Sterner CJ, Belka GK,
Wang D, Xu P, Sreekumar A, Pan T, Pant DK, Makhlin I, et al: PAQR8
promotes breast cancer recurrence and confers resistance to
multiple therapies. Breast Cancer Res. 25:12023. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Azria D, Brengues M, Gourgou S and
Bourgier C: Personalizing breast cancer irradiation using biology:
From bench to the accelerator. Front Oncol. 8:832018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Vaidya JS, Bulsara M, Baum M, Wenz F,
Massarut S, Pigorsch S, Alvarado M, Douek M, Saunders C, Flyger HL,
et al: Long term survival and local control outcomes from single
dose targeted intraoperative radiotherapy during lumpectomy
(TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical
trial. BMJ. 370:m28362020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sousa C, Cruz M, Neto A, Pereira K,
Peixoto M, Bastos J, Henriques M, Roda D, Marques R, Miranda C, et
al: Neoadjuvant radiotherapy in the approach of locally advanced
breast cancer. ESMO Open. 4 (Suppl 2):e0006402020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Huang RX and Zhou PK: DNA damage response
signaling pathways and targets for radiotherapy sensitization in
cancer. Signal Transduct Target Ther. 5:602020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu Y, Song Y, Wang R and Wang T: Molecular
mechanisms of tumor resistance to radiotherapy. Mol Cancer.
22:962023. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu J, Bi K, Yang R, Li H, Nikitaki Z and
Chang L: Role of DNA damage and repair in radiation cancer therapy:
A current update and a look to the future. Int J Radiat Biol.
96:1329–1338. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Piotto C, Biscontin A, Millino C and
Mognato M: Functional validation of miRNAs targeting genes of DNA
double-strand break repair to radiosensitize non-small lung cancer
cells. Biochim Biophys Acta Gene Regul Mech. 1861:1102–1118. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Santivasi WL and Xia F: Ionizing
radiation-induced DNA damage, response, and repair. Antioxid Redox
Signal. 21:251–259. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
van Oorschot B, Granata G, Di Franco S,
Ten Cate R, Rodermond HM, Todaro M, Medema JP and Franken NAP:
Targeting DNA double strand break repair with hyperthermia and
DNA-PKcs inhibition to enhance the effect of radiation treatment.
Oncotarget. 7:65504–65513. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dietlein F, Thelen L and Reinhardt HC:
Cancer-specific defects in DNA repair pathways as targets for
personalized therapeutic approaches. Trends Genet. 30:326–339.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mekonnen N, Yang H and Shin YK: Homologous
recombination deficiency in ovarian, breast, colorectal,
pancreatic, non-small cell lung and prostate cancers, and the
mechanisms of resistance to PARP inhibitors. Front Oncol.
12:8806432022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Panier S and Boulton SJ: Double-strand
break repair: 53BP1 comes into focus. Nat Rev Mol Cell Biol.
15:7–18. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tian J, Wen M, Gao P, Feng M and Wei G:
RUVBL1 ubiquitination by DTL promotes RUVBL1/2-β-catenin-mediated
transcriptional regulation of NHEJ pathway and enhances radiation
resistance in breast cancer. Cell Death Dis. 15:2592024. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chan Wah Hak CML, Rullan A, Patin EC,
Pedersen M, Melcher AA and Harrington KJ: Enhancing anti-tumour
innate immunity by targeting the DNA damage response and pattern
recognition receptors in combination with radiotherapy. Front
Oncol. 12:9719592022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Karess RE, Wassmann K and Rahmani Z: New
insights into the role of BubR1 in mitosis and beyond. Int Rev Cell
Mol Biol. 306:223–273. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jiao CY, Feng QC, Li CX, Wang D, Han S,
Zhang YD, Jiang WJ, Chang J, Wang X and Li XC: BUB1B promotes
extrahepatic cholangiocarcinoma progression via JNK/c-Jun pathways.
Cell Death Dis. 12:632021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhou X, Yuan Y, Kuang H, Tang B, Zhang H
and Zhang M: BUB1B (BUB1 mitotic checkpoint serine/threonine kinase
B) promotes lung adenocarcinoma by interacting with zinc finger
protein ZNF143 and regulating glycolysis. Bioengineered.
13:2471–2485. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yan HC and Xiang C: Aberrant expression of
BUB1B contributes to the progression of thyroid carcinoma and
predicts poor outcomes for patients. J Cancer. 13:2336–2351. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ma Q, Liu Y, Shang L, Yu J and Qu Q: The
FOXM1/BUB1B signaling pathway is essential for the tumorigenicity
and radioresistance of glioblastoma. Oncol Rep. 38:3367–3375.
2017.PubMed/NCBI
|
|
23
|
Komura K, Inamoto T, Tsujino T, Matsui Y,
Konuma T, Nishimura K, Uchimoto T, Tsutsumi T, Matsunaga T,
Maenosono R, et al: Increased BUB1B/BUBR1 expression contributes to
aberrant DNA repair activity leading to resistance to DNA-damaging
agents. Oncogene. 40:6210–6222. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tang X, Guo M, Ding P, Deng Z, Ke M, Yuan
Y, Zhou Y, Lin Z, Li M, Gu C, et al: BUB1B and circBUB1B_544aa
aggravate multiple myeloma malignancy through evoking chromosomal
instability. Signal Transduct Target Ther. 6:3612021. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Komatsu M, Yoshimaru T, Matsuo T, Kiyotani
K, Miyoshi Y, Tanahashi T, Rokutan K, Yamaguchi R, Saito A, Imoto
S, et al: Molecular features of triple negative breast cancer cells
by genome-wide gene expression profiling analysis. Int J Oncol.
42:478–506. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Maubant S, Tesson B, Maire V, Ye M,
Rigaill G, Gentien D, Cruzalegui F, Tucker GC, Roman-Roman S and
Dubois T: Transcriptome analysis of Wnt3a-treated triple-negative
breast cancer cells. PLoS One. 10:e01223332015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Końca K, Lankoff A, Banasik A, Lisowska H,
Kuszewski T, Góźdź S, Koza Z and Wojcik A: A cross-platform public
domain PC image-analysis program for the comet assay. Mutat Res.
534:15–20. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ho SY, Wu WS, Lin LC, Wu YH, Chiu HW, Yeh
YL, Huang BM and Wang YJ: Cordycepin enhances radiosensitivity in
oral squamous carcinoma cells by inducing autophagy and apoptosis
through cell cycle arrest. Int J Mol Sci. 20:53662019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Liu T, Wang H, Chen Y, Wan Z, Du Z, Shen
H, Yu Y, Ma S, Xu Y, Li Z, et al: SENP5 promotes homologous
recombination-mediated DNA damage repair in colorectal cancer cells
through H2AZ deSUMOylation. J Exp Clin Cancer Res. 42:2342023.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Qiu J, Zhang S, Wang P, Wang H, Sha B,
Peng H, Ju Z, Rao J and Lu L: BUB1B promotes hepatocellular
carcinoma progression via activation of the mTORC1 signaling
pathway. Cancer Med. 9:8159–8172. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sekino Y, Han X, Kobayashi G, Babasaki T,
Miyamoto S, Kobatake K, Kitano H, Ikeda K, Goto K, Inoue S, et al:
BUB1B overexpression is an independent prognostic marker and
associated with CD44, p53, and PD-L1 in renal cell carcinoma.
Oncology. 99:240–250. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Koyuncu D, Sharma U, Goka ET and Lippman
ME: Spindle assembly checkpoint gene BUB1B is essential in breast
cancer cell survival. Breast Cancer Res Treat. 185:331–341. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mladenov E, Mladenova V, Stuschke M and
Iliakis G: New facets of DNA double strand break repair: Radiation
dose as key determinant of HR versus c-NHEJ engagement. Int J Mol
Sci. 24:149562023. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hu C, Bugbee T, Dacus D, Palinski R and
Wallace N: Beta human papillomavirus 8 E6 allows colocalization of
non-homologous end joining and homologous recombination repair
factors. PLoS Pathog. 18:e10102752022. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhou K, Wu C, Cheng W, Zhang B, Wei R,
Cheng D, Li Y, Cao Y, Zhang W, Yao Z and Zhang X: Transglutaminase
3 regulates cutaneous squamous carcinoma differentiation and
inhibits progression via PI3K-AKT signaling pathway-mediated
Keratin 14 degradation. Cell Death Dis. 15:2522024. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zheng D, Zhu G, Liao S, Yi W, Luo G, He J,
Pei Z, Li G and Zhou Y: Dysregulation of the PI3K/Akt signaling
pathway affects cell cycle and apoptosis of side population cells
in nasopharyngeal carcinoma. Oncol Lett. 10:182–188. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dong J, Ru Y, Zhai L, Gao Y, Guo X, Chen B
and Lv X: LMNB1 deletion in ovarian cancer inhibits the
proliferation and metastasis of tumor cells through PI3K/Akt
pathway. Exp Cell Res. 426:1135732023. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dong C, Wu J, Chen Y, Nie J and Chen C:
Activation of PI3K/AKT/mTOR pathway causes drug resistance in
breast cancer. Front Pharmacol. 12:6286902021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chen Q, Zheng W, Zhu L, Yao D, Wang C,
Song Y, Hu S, Liu H, Bai Y, Pan Y, et al: ANXA6 contributes to
radioresistance by promoting autophagy via inhibiting the
PI3K/AKT/mTOR signaling pathway in nasopharyngeal carcinoma. Front
Cell Dev Biol. 8:2322020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chen K, Shang Z, Dai AL and Dai PL: Novel
PI3K/Akt/mTOR pathway inhibitors plus radiotherapy: Strategy for
non-small cell lung cancer with mutant RAS gene. Life Sci.
255:1178162020. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yu CC, Hung SK, Lin HY, Chiou WY, Lee MS,
Liao HF, Huang HB, Ho HC and Su YC: Targeting the PI3K/AKT/mTOR
signaling pathway as an effectively radiosensitizing strategy for
treating human oral squamous cell carcinoma in vitro and in vivo.
Oncotarget. 8:68641–68653. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gil del Alcazar CR, Hardebeck MC,
Mukherjee B, Tomimatsu N, Gao X, Yan J, Xie XJ, Bachoo R, Li L,
Habib AA and Burma S: Inhibition of DNA double-strand break repair
by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for
radiosensitization of glioblastoma. Clin Cancer Res. 20:1235–1248.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kao GD, Jiang Z, Fernandes AM, Gupta AK
and Maity A: Inhibition of phosphatidylinositol-3-OH kinase/Akt
signaling impairs DNA repair in glioblastoma cells following
ionizing radiation. J Biol Chem. 282:21206–21212. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
No M, Choi EJ and Kim IA: Targeting HER2
signaling pathway for radiosensitization: Alternative strategy for
therapeutic resistance. Cancer Biol Ther. 8:2351–2361. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Sun Y, Dong D, Xia Y, Hao L, Wang W and
Zhao C: YTHDF1 promotes breast cancer cell growth, DNA damage
repair and chemoresistance. Cell Death Dis. 13:2302022. View Article : Google Scholar : PubMed/NCBI
|
